<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p155" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_155{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_155{left:306px;bottom:30px;}
#t3_155{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_155{left:346px;bottom:30px;}
#t5_155{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_155{left:517px;bottom:30px;}
#t7_155{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_155{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_155{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_155{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_155{left:35px;bottom:777px;letter-spacing:0.13px;word-spacing:0.06px;}
#tc_155{left:35px;bottom:754px;letter-spacing:0.1px;word-spacing:0.09px;}
#td_155{left:35px;bottom:731px;letter-spacing:-0.08px;}
#te_155{left:76px;bottom:738px;letter-spacing:0.12px;}
#tf_155{left:164px;bottom:731px;letter-spacing:0.01px;word-spacing:0.18px;}
#tg_155{left:35px;bottom:707px;letter-spacing:0.1px;word-spacing:0.08px;}
#th_155{left:35px;bottom:684px;letter-spacing:0.09px;word-spacing:0.1px;}
#ti_155{left:35px;bottom:645px;letter-spacing:0.06px;word-spacing:0.12px;}
#tj_155{left:35px;bottom:622px;letter-spacing:0.05px;word-spacing:-1.1px;}
#tk_155{left:35px;bottom:599px;letter-spacing:0.14px;word-spacing:0.04px;}
#tl_155{left:35px;bottom:575px;letter-spacing:0.14px;word-spacing:0.05px;}
#tm_155{left:35px;bottom:552px;letter-spacing:0.04px;word-spacing:-1.08px;}
#tn_155{left:35px;bottom:529px;letter-spacing:0.16px;word-spacing:0.03px;}
#to_155{left:35px;bottom:506px;letter-spacing:0.08px;word-spacing:-1.13px;}
#tp_155{left:529px;bottom:513px;letter-spacing:-0.01px;}
#tq_155{left:35px;bottom:482px;letter-spacing:0.01px;word-spacing:-0.65px;}
#tr_155{left:35px;bottom:459px;letter-spacing:0.13px;word-spacing:0.05px;}
#ts_155{left:35px;bottom:436px;letter-spacing:0.16px;word-spacing:0.03px;}
#tt_155{left:35px;bottom:396px;letter-spacing:0.1px;word-spacing:0.09px;}
#tu_155{left:35px;bottom:372px;letter-spacing:0.11px;word-spacing:0.08px;}
#tv_155{left:35px;bottom:349px;letter-spacing:0.1px;word-spacing:-0.62px;}
#tw_155{left:35px;bottom:326px;letter-spacing:0.18px;}
#tx_155{left:35px;bottom:303px;letter-spacing:0.07px;word-spacing:-1.12px;}
#ty_155{left:35px;bottom:280px;letter-spacing:0.09px;word-spacing:0.1px;}
#tz_155{left:35px;bottom:256px;letter-spacing:0.16px;word-spacing:0.03px;}
#t10_155{left:35px;bottom:218px;letter-spacing:-0.06px;word-spacing:0.48px;}
#t11_155{left:35px;bottom:194px;letter-spacing:0.11px;word-spacing:-0.85px;}
#t12_155{left:35px;bottom:171px;letter-spacing:0.02px;word-spacing:0.17px;}
#t13_155{left:35px;bottom:148px;letter-spacing:0.12px;word-spacing:0.07px;}
#t14_155{left:35px;bottom:124px;letter-spacing:0.14px;}
#t15_155{left:136px;bottom:132px;letter-spacing:-0.11px;}
#t16_155{left:178px;bottom:124px;letter-spacing:0.06px;word-spacing:-1.1px;}
#t17_155{left:35px;bottom:101px;letter-spacing:0.1px;word-spacing:0.09px;}
#t18_155{left:524px;bottom:109px;}
#t19_155{left:35px;bottom:78px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1a_155{left:35px;bottom:55px;letter-spacing:-0.02px;word-spacing:-0.29px;}
#t1b_155{left:618px;bottom:777px;letter-spacing:0.11px;word-spacing:-0.78px;}
#t1c_155{left:618px;bottom:754px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1d_155{left:618px;bottom:731px;letter-spacing:0.1px;}
#t1e_155{left:654px;bottom:738px;letter-spacing:0.1px;}
#t1f_155{left:618px;bottom:690px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1g_155{left:618px;bottom:667px;letter-spacing:0.09px;word-spacing:0.11px;}
#t1h_155{left:618px;bottom:645px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1i_155{left:618px;bottom:622px;letter-spacing:0.17px;word-spacing:-0.13px;}
#t1j_155{left:618px;bottom:599px;letter-spacing:0.14px;word-spacing:-0.88px;}
#t1k_155{left:618px;bottom:575px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t1l_155{left:618px;bottom:552px;letter-spacing:0.07px;word-spacing:-0.16px;}
#t1m_155{left:618px;bottom:529px;letter-spacing:0.04px;word-spacing:0.27px;}
#t1n_155{left:618px;bottom:506px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1o_155{left:911px;bottom:506px;}
#t1p_155{left:926px;bottom:506px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1q_155{left:618px;bottom:482px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1r_155{left:837px;bottom:490px;letter-spacing:-0.01px;}
#t1s_155{left:860px;bottom:482px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1t_155{left:618px;bottom:459px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1u_155{left:1051px;bottom:459px;}
#t1v_155{left:1067px;bottom:459px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t1w_155{left:1117px;bottom:467px;letter-spacing:-0.01px;}
#t1x_155{left:618px;bottom:436px;letter-spacing:0.08px;word-spacing:-1.13px;}
#t1y_155{left:618px;bottom:413px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1z_155{left:618px;bottom:390px;letter-spacing:0.14px;word-spacing:-0.47px;}
#t20_155{left:618px;bottom:366px;letter-spacing:0.12px;word-spacing:0.07px;}
#t21_155{left:618px;bottom:343px;letter-spacing:0.05px;word-spacing:0.13px;}
#t22_155{left:618px;bottom:320px;letter-spacing:0.08px;word-spacing:0.1px;}
#t23_155{left:859px;bottom:320px;}
#t24_155{left:875px;bottom:320px;letter-spacing:0.08px;word-spacing:0.1px;}
#t25_155{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:0.07px;}
#t26_155{left:1085px;bottom:297px;}
#t27_155{left:1101px;bottom:297px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t28_155{left:618px;bottom:273px;letter-spacing:0.05px;}
#t29_155{left:618px;bottom:250px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2a_155{left:1109px;bottom:258px;letter-spacing:-0.01px;}
#t2b_155{left:618px;bottom:210px;letter-spacing:0.19px;}
#t2c_155{left:618px;bottom:187px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2d_155{left:618px;bottom:163px;letter-spacing:0.11px;word-spacing:-0.65px;}
#t2e_155{left:1054px;bottom:171px;letter-spacing:0.12px;}
#t2f_155{left:1121px;bottom:163px;letter-spacing:0.39px;word-spacing:-0.21px;}
#t2g_155{left:618px;bottom:140px;letter-spacing:0.12px;word-spacing:0.08px;}
#t2h_155{left:618px;bottom:117px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2i_155{left:618px;bottom:94px;letter-spacing:0.08px;word-spacing:-0.8px;}
#t2j_155{left:618px;bottom:71px;letter-spacing:0.14px;word-spacing:0.04px;}
#t2k_155{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_155{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_155{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_155{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_155{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_155{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_155{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_155{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s7_155{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s8_155{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts155" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg155Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg155" style="-webkit-user-select: none;"><object width="1210" height="935" data="155/155.svg" type="image/svg+xml" id="pdf155" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_155" class="t s0_155">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_155" class="t s1_155">© </span>
<span id="t3_155" class="t s0_155">(NCCN </span>
<span id="t4_155" class="t s1_155">© </span>
<span id="t5_155" class="t s0_155">), All rights reserved. NCCN Guidelines </span>
<span id="t6_155" class="t s1_155">® </span>
<span id="t7_155" class="t s0_155">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_155" class="t s2_155">NCCN Guidelines Version 4.2024 </span>
<span id="t9_155" class="t s2_155">Head and Neck Cancers </span>
<span id="ta_155" class="t s3_155">MS-14 </span>
<span id="tb_155" class="t s4_155">Hypofractionation, when RT is given at &gt;3.0 Gy/fraction, has been </span>
<span id="tc_155" class="t s4_155">reported in some single institutional experiences and clinical </span>
<span id="td_155" class="t s4_155">trials, </span>
<span id="te_155" class="t s5_155">146,147,157,158 </span>
<span id="tf_155" class="t s4_155">but a lack of high-level randomized comparator data and </span>
<span id="tg_155" class="t s4_155">concerns about the possibility of long-term late toxicity have limited its </span>
<span id="th_155" class="t s4_155">widespread adoption to date. </span>
<span id="ti_155" class="t s4_155">Postoperative irradiation is recommended based on stage, histology, and </span>
<span id="tj_155" class="t s4_155">surgical-pathologic findings. In general, postoperative RT is recommended </span>
<span id="tk_155" class="t s4_155">for selected risk factors, including advanced T stage, close surgical </span>
<span id="tl_155" class="t s4_155">margins, depth or extent of invasion, multiple positive nodes, or </span>
<span id="tm_155" class="t s4_155">perineural/lymphovascular invasion. High doses of postoperative RT alone </span>
<span id="tn_155" class="t s4_155">(eg, 66 Gy) and/or systemic therapy/RT are recommended for the </span>
<span id="to_155" class="t s4_155">high-risk features of extranodal extension and/or positive margins. </span>
<span id="tp_155" class="t s5_155">136,137,151 </span>
<span id="tq_155" class="t s4_155">Particularly for these high-risk cases, the preferred maximum elapsed time </span>
<span id="tr_155" class="t s4_155">interval between surgical resection and the start of postoperative RT is 6 </span>
<span id="ts_155" class="t s4_155">weeks or less. </span>
<span id="tt_155" class="t s4_155">Postoperative radiation fractionation schedules tend to be similar (60–66 </span>
<span id="tu_155" class="t s4_155">Gy at 2 Gy/fraction) whether or not systemic therapy is administered </span>
<span id="tv_155" class="t s4_155">concurrently with postoperative RT. Hypofractionation may be considered </span>
<span id="tw_155" class="t s4_155">for patients who are not good candidates for an extended course of </span>
<span id="tx_155" class="t s4_155">several weeks of RT due to resource limitations or comorbidities, but these </span>
<span id="ty_155" class="t s4_155">schedules have not been widely adopted as late effects are a particular </span>
<span id="tz_155" class="t s4_155">concern in the postoperative population. </span>
<span id="t10_155" class="t s6_155">Fractionation in RT Alone </span>
<span id="t11_155" class="t s4_155">No single fractionation schedule has proven to be best for all tumors. Data </span>
<span id="t12_155" class="t s4_155">strongly indicate that SCCHN can grow rapidly and may compensate for </span>
<span id="t13_155" class="t s4_155">RT-induced cell loss through the mechanism of accelerated </span>
<span id="t14_155" class="t s4_155">repopulation. </span>
<span id="t15_155" class="t s5_155">159,160 </span>
<span id="t16_155" class="t s4_155">Especially in the RT-alone setting, schedules delivering </span>
<span id="t17_155" class="t s4_155">at least 1000 cGy per week to gross disease are recommended, </span>
<span id="t18_155" class="t s5_155">161-163 </span>
<span id="t19_155" class="t s4_155">although it is acknowledged that some tumors such as those of the </span>
<span id="t1a_155" class="t s4_155">salivary gland may have slower cell kinetics. Trials in early-stage laryngeal </span>
<span id="t1b_155" class="t s4_155">glottic cancer have shown higher recurrence rates with daily fraction sizes </span>
<span id="t1c_155" class="t s4_155">less than 200 cGy where the cumulative weekly dose is less than 1000 </span>
<span id="t1d_155" class="t s4_155">cGy. </span>
<span id="t1e_155" class="t s5_155">164,165 </span>
<span id="t1f_155" class="t s4_155">Two large, randomized trials from Europe have reported improved </span>
<span id="t1g_155" class="t s4_155">locoregional control using altered fractionation as compared to </span>
<span id="t1h_155" class="t s4_155">conventional fractionation, when concurrent chemotherapy is not given. </span>
<span id="t1i_155" class="t s4_155">The EORTC protocol 22791 compared hyperfractionation (1.15 Gy twice </span>
<span id="t1j_155" class="t s4_155">daily, or 80.5 Gy over 7 weeks) with conventional fractionation (2 Gy once </span>
<span id="t1k_155" class="t s4_155">daily, or 70 Gy over 7 weeks) in the treatment of T2, T3, N0–1 </span>
<span id="t1l_155" class="t s4_155">oropharyngeal carcinoma excluding base of tongue primaries. At 5 years, </span>
<span id="t1m_155" class="t s4_155">a statistically significant increase in local control was observed in the </span>
<span id="t1n_155" class="t s4_155">hyperfractionation arm (38% vs. 56%; </span><span id="t1o_155" class="t s7_155">P </span><span id="t1p_155" class="t s4_155">= .01) and no increase in late </span>
<span id="t1q_155" class="t s4_155">complications was observed. </span>
<span id="t1r_155" class="t s5_155">166 </span>
<span id="t1s_155" class="t s4_155">A long-term follow-up analysis has also </span>
<span id="t1t_155" class="t s4_155">shown a small survival advantage for hyperfractionation (</span><span id="t1u_155" class="t s7_155">P </span><span id="t1v_155" class="t s4_155">= .05). </span>
<span id="t1w_155" class="t s5_155">167 </span>
<span id="t1x_155" class="t s4_155">Another EORTC protocol (22851) compared accelerated fractionation (1.6 </span>
<span id="t1y_155" class="t s4_155">Gy 3 times daily, or 72 Gy over 5 weeks) with conventional fractionation </span>
<span id="t1z_155" class="t s4_155">(1.8–2.0 Gy once daily, or 70 Gy over 7–8 weeks) in various intermediate </span>
<span id="t20_155" class="t s4_155">to advanced H&amp;N cancers (excluding cancers of the hypopharynx). </span>
<span id="t21_155" class="t s4_155">Patients in the accelerated fractionation arm had significantly better </span>
<span id="t22_155" class="t s4_155">locoregional control at 5 years (</span><span id="t23_155" class="t s7_155">P </span><span id="t24_155" class="t s4_155">= .02). Disease-specific survival (DSS) </span>
<span id="t25_155" class="t s4_155">showed a trend in favor of the accelerated fractionation arm (</span><span id="t26_155" class="t s7_155">P </span><span id="t27_155" class="t s4_155">= .06). </span>
<span id="t28_155" class="t s4_155">However, acute and late toxicity were increased with acceleration, raising </span>
<span id="t29_155" class="t s4_155">questions about the net advantages of accelerated fractionation. </span>
<span id="t2a_155" class="t s5_155">168 </span>
<span id="t2b_155" class="t s4_155">The RTOG reported the results of a four-arm, phase III, randomized </span>
<span id="t2c_155" class="t s4_155">clinical trial (RTOG 90-03) comparing hyperfractionation and two variants </span>
<span id="t2d_155" class="t s4_155">of accelerated fractionation versus standard fractionation. </span>
<span id="t2e_155" class="t s5_155">148,149,169 </span>
<span id="t2f_155" class="t s4_155">After 2 </span>
<span id="t2g_155" class="t s4_155">years of follow-up, both accelerated fractionation using a concomitant </span>
<span id="t2h_155" class="t s4_155">boost (AFX-C) and hyperfractionation were associated with improved </span>
<span id="t2i_155" class="t s4_155">locoregional control and DFS compared with standard fractionation. Acute </span>
<span id="t2j_155" class="t s4_155">toxicity was increased with both of these regimens. However, no </span>
<span id="t2k_155" class="t s8_155">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
